Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
Liu X, Xu Y, Xiong W, Yin B, Huang Y, Chu J, Xing C, Qian C, Du Y, Duan T, Wang HY, Zhang N, Yu JS, An Z, Wang R.
Liu X, et al. Among authors: an z.
J Immunother Cancer. 2022 Mar;10(3):e004035. doi: 10.1136/jitc-2021-004035.
J Immunother Cancer. 2022.
PMID: 35338087
Free PMC article.